COLL vs ENOV: Which Stock Is the Better Buy?
Collegium Pharmaceutical, Inc. and Enovis Corporation side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — COLL vs ENOV, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Collegium Pharmaceutical, Inc. (COLL) | Enovis Corporation (ENOV) | |
|---|---|---|
| Market cap | $1.1B | $1.3B |
| Revenue (latest FY) | $780.57M | $2.25B |
| Net income (latest FY) | $62.87M | $-1.18B |
| Revenue growth (5y CAGR) | 20.3% | 14.9% |
| Net margin | 8.1% | -52.7% |
| Return on equity | 20.8% | -79.5% |
| P/E ratio | 16.8 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 5 | 5 |
| Positive free cash flow | Yes | Yes |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full COLL vs ENOV breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open COLL's full financials → Open ENOV's full financials →More comparisons
Frequently asked questions
Which is bigger, COLL or ENOV?
Enovis Corporation is larger by market capitalization — $1.3B versus $1.1B.
Which grows faster, COLL or ENOV?
Over the last five fiscal years, Collegium Pharmaceutical, Inc. grew revenue faster — 20.3%/yr versus 14.9%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.